Evonik Industries AG · XETR:EVK

Evonik Industries — Q1 2018 Earnings Presentation

89 slides from Evonik Industries's earnings presentation, May 2018

  1. Slide 1: Evonik Company presentation Q1 2018 Results Roadshow

    Slide 1: Evonik Company presentation Q1 2018 Results Roadshow

    Evonik Power to create. Portfolio Company presentation Profitable Growth Q1 2018 Results Roadshow Innovation Culture 1

  2. Slide 2: Table of contents

    Slide 2: Table of contents

    Table of contents 1. Evonik at a glance 2. Strategy 3. Financials Q1 2018 4. Appendix 2

  3. Slide 3: A strong basis in Specialty Chemicals

    Slide 3: A strong basis in Specialty Chemicals

    A strong basis in Specialty Chemicals Market Customer Technology Unique brand Qualified leadership proximity leadership recognition employees Leading market Leading and Highly qualified Almost 90% positions in proprietary technology of direct sales platforms in workforce 80% via as key factor for a

  4. Slide 4: Three segments with differentiated management

    Slide 4: Three segments with differentiated management

    Three segments with differentiated management Group financials 2017 Sales Adj. EBITDA Margin ROCE €14,383 m €2,357 m 16.4% 11.2% Growth Efficiency Nutrition Resource Performance & Care Efficiency Materials Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin €4,507 m €747

  5. Slide 5: Balanced regional and end market split

    Slide 5: Balanced regional and end market split

    Balanced regional and end market split Sales by region End market split Agriculture Renewable energies Other Electrical & electronics Western Europe Paper & printing Metal & oil products Food & animal feed Asia-Pacific Paints & coatings1 Other industries Pharmaceuticals Consumer & Central & South Am

  6. Slide 6: Evonik management team with clear responsibilities

    Slide 6: Evonik management team with clear responsibilities

    Evonik management team with clear responsibilities Executive Board Group Strategy Chemistry & Innovation Financials HR Christian Dr. Harald Ute Thomas Kullmann Schwager Wolf Wessel Chairman of the Deputy Chairman Chief Financial Chief Human Executive Board of the Executive Officer Resources Officer

  7. Slide 7: RAG-Stiftung as long-term shareholder

    Slide 7: RAG-Stiftung as long-term shareholder

    “RAG-Stiftung” as long-term shareholder with focus on attractive returns Ownership structure RAG-Stiftung  A foundation with the obligation to finance the perpetual liabilities arising from the cessation of hard-coal mining in Germany  From 2019 onwards, annual cash out of ~€220 m expected Free fl

  8. Slide 8: Reliable and attractive dividend policy

    Slide 8: Reliable and attractive dividend policy

    Reliable and attractive dividend policy Payout ratio 48% 58% 53%  Sustainable dividend growth over the last years: 7% CAGR between 2008 and 2017 Dividend (in €) for FY 1.15 1.15 1.15  Attractive dividend yield ~ 3.7% +7% CAGR  Reliable dividend policy targeting:  dividend continuity  a payout r

  9. Slide 9: Table of contents

    Slide 9: Table of contents

    Table of contents 1. Evonik at a glance 2. Strategy 3. Financials Q1 2018 4. Appendix 9

  10. Slide 10: Building a best-in-class specialty chemicals company

    Slide 10: Building a best-in-class specialty chemicals company

    Building a best-in-class specialty chemicals company 10

  11. Slide 11: Targeting excellence in three strategic focus areas

    Slide 11: Targeting excellence in three strategic focus areas

    Targeting excellence in three strategic focus areas Portfolio: More balanced & more specialty Profitable Growth Open & Leading in performance-oriented innovation culture 11

  12. Slide 12: Building on our strengths

    Slide 12: Building on our strengths

    Building on our strengths Developing our growth segments and businesses NUTRITION & CARE RESOURCE EFFICIENCY PERFORMANCE MATERIALS €4.5 bn €5.4 bn €3.8 bn Mature Mature Mature businesses businesses businesses Growth Growth businesses businesses Meeting specialty chemicals characteristics Focus of ca

  13. Slide 13: Strategic growth focus: four growth engines

    Slide 13: Strategic growth focus: four growth engines

    Strategic growth focus Four growth engines as drivers for profitable & balanced growth NUTRITION & CARE RESOURCE EFFICIENCY Health & Care Smart Materials Four growth Specialty Additives engines Animal Nutrition 13

  14. Slide 14: Strategic agenda reflected in ambitious financial targets

    Slide 14: Strategic agenda reflected in ambitious financial targets

    Strategic agenda reflected in ambitious financial targets Structurally lifting EBITDA margin and driving balanced growth Historic margin range (in %) Targets going forward (over the cycle) Structurally lift EBITDA margin 19.0 into sustainably higher range of 18-20% 18.3 18.5 18.2 16.4 Above-average

  15. Slide 15: Consistently executing our strategic agenda

    Slide 15: Consistently executing our strategic agenda

    Consistently executing our strategic agenda Levers for structural uplift in profitability and growth Strategic lever Impact (p.a.) by (year) Synergy  Realization of synergies from Air Products €85 m 2020/ and J.M. Huber acquisitions EBITDA1 2021 realization Cost  Leaner processes, higher cost disc

  16. Slide 16: Table of contents

    Slide 16: Table of contents

    Table of contents 1. Evonik at a glance 2. Strategy 3. Financials Q1 2018 4. Appendix 16

  17. Slide 17: Our agenda for 2018 – Driving the change

    Slide 17: Our agenda for 2018 – Driving the change

    Our agenda for 2018 – Driving the change Steady progress on strategy execution Strategy execution  Divestment of Methacrylates business  Strengthening “Smart Materials” via PA12 investment 1  €200 m cost savings in SG&A  Optimized strategic positioning for Animal Nutrition  Driving an open and

  18. Slide 18: Highlights Q1 2018

    Slide 18: Highlights Q1 2018

    Highlights Q1 2018 Good start into the year, strong earnings and margin growth, higher FCF Volume growth Adj. EBITDA and Free cash flow Outlook margin confirmed +1% €679 m (+14%1) €84 m €2.4-2.6 bn 18.5% (+2.1pp1) Good volumes in Nutrition & Strong earnings and margin FCF above prior year Good start

  19. Slide 19: Financial highlights Q1 2018

    Slide 19: Financial highlights Q1 2018

    Financial highlights Q1 2018 Good quarterly performance reflected in all KPI’s Sales +1% Q1 18 vs. Q1 17 Adj. EBITDA (in € m) +14% (in € m) 3,636 3,678 / margin (in %) 595 679 Volume Price +1%   +4%  FX Other1 in % 16.4 18.5 Q1 17 Q1 18 -5%  +1%   Q1 17 Q1 18 +34% Adj. EPS Net financial +39 (i

  20. Slide 20: Earnings development Q1 2018

    Slide 20: Earnings development Q1 2018

    Earnings development Q1 2018 Earnings and margin expansion in all segments despite material headwinds – +  Significant FX headwind in all segments  Healthy underlying trends in most businesses  Higher raw material prices  Synergy realization from Air Products and Huber  First effects from cost

  21. Slide 21: Resource Efficiency

    Slide 21: Resource Efficiency

    Resource Efficiency Business strength proven by sustained high margin level Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +3% +9% 1,360 1,367 1,358 1,398 318 311 325 1,308 297 247 21.8 23.3 22.9 18.9 23.2 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18  Successful management of ra

  22. Slide 22: Nutrition & Care

    Slide 22: Nutrition & Care

    Nutrition & Care Healthy organic growth leading to higher earnings and margin expansion Sales (in € m) Adj. EBITDA (in € m) / margin (in %) 0% +12% 1,120 1,163 1,110 1,114 1,119 201 209 187 188 172 16.7 17.3 16.9 15.4 18.7 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18  Overall, good o

  23. Slide 23: Performance Materials

    Slide 23: Performance Materials

    Performance Materials Another strong quarter driven by Methacrylates Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +4% +14% 959 970 995 168 172 179 910 913 157 161 16.4 18.5 18.8 16.6 18.0 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18  Negative FX effect (mainly in MMA/PMMA busi

  24. Slide 24: Outlook 2018

    Slide 24: Outlook 2018

    Outlook 2018 Committed to higher sales and earnings growth Outlook FY 2018 Sales Slightly higher sales 2017: €14.4 bn Adj. EBITDA €2.4 – 2.6 bn 2017: €2,357 m FX assumption 1.26 EUR/USD (from 1.20 at Q4 17 reporting) Outlook fully confirmed, despite more negative FX assumption Adj. EBITDA for Q2 exp

  25. Slide 25: Free Cash Flow Q1 2018

    Slide 25: Free Cash Flow Q1 2018

    Free Cash Flow Q1 2018 Free cash flow above prior-year level Operating Cash Flow Investing Cash Flow Free Cash Flow (cont. op. in € m) (cont. op. in € m)1 (cont. op. in € m)2 (before dividends and divestments)  Lower capex spending despite 84 277 277 investment in new Methionine plant 57 Q1 2017 Q1

  26. Slide 26: Additional indications for 2018

    Slide 26: Additional indications for 2018

    Additional indications for 2018  Synergies from acquisitions Additional synergies of ~€25 m (Synergies 2018e: ~€40 m; 2017: ~€15 m) (APD Specialty Chemicals & Huber Silica)  Huber Additional adj. EBITDA of ~€30 m for further eight months of consolidation (closing Sept 1st 2017)  ROCE Above cost o

  27. Slide 27: © evonik

    Slide 27: © evonik

    © evonik

  28. Slide 28: Appendix

    Slide 28: Appendix

    Appendix 1. Strategy Details 2. Segment overview 3. Financials 4. Upcoming events 28

  29. Slide 29: Targeting excellence in three strategic focus areas

    Slide 29: Targeting excellence in three strategic focus areas

    Targeting excellence in three strategic focus areas Portfolio: More balanced & more specialty Profitable Growth Open & Leading in performance-oriented innovation culture 29

  30. Slide 30: Portfolio strategy: More balanced – more specialty

    Slide 30: Portfolio strategy: More balanced – more specialty

    Portfolio strategy: „More balanced – more specialty“ Focus on businesses with specialty chemicals characteristics Low cyclicality; Customer-specific products low raw material dependency and services Above- average growth and margins Mission-critical solutions High customer proximity enabling value-b

  31. Slide 31: Executing portfolio management on all levels

    Slide 31: Executing portfolio management on all levels

    Executing portfolio management on all levels Building a more balanced and more specialty portfolio Implemented and initiated measures Major portfolio steps  Acquisition of Air Products Specialty Additives  Divestment of Methacrylates business Bolt-on M&A and divestments  Acquisition of Huber Sili

  32. Slide 32: Four growth engines

    Slide 32: Four growth engines

    Four growth engines Growth drivers and product examples Growth trends and drivers Product examples Market growth  More sophisticated requirements on additive effects Coating Additives Specialty Additives  Need for increased product performance and PU-Additives 5-6% “Small volume, big impact” effic

  33. Slide 33: Targeted and disciplined M&A approach

    Slide 33: Targeted and disciplined M&A approach

    Targeted and disciplined M&A approach Air Products Huber Silica Dr. Straetmans Performance Materials Purchase price ~ €3.5 bn ~ €600 m ~ €100 m EBITDA margin >20% >20% ~20% Market growth ~4-5% ~4-6% ~10% Business Highly attractive strategic fit, seamless integration into existing businesses Discipli

  34. Slide 34: Achieving cost excellence

    Slide 34: Achieving cost excellence

    Achieving cost excellence Leaner processes, higher cost discipline and increased performance orientation Cost savings of €200 m (p.a.) €50 m  €135 m Structural changes to secure sustainable impact  Hiring freeze in General &  Streamlining of major end-to-end processes relevant functions Admin  S

  35. Slide 35: Implementation schedule for acquisition synergies

    Slide 35: Implementation schedule for acquisition synergies

    Implementation schedule for acquisition synergies Ramp-up on track for Air Products specialty additives and Huber silica acquisitions Implementation schedule (in € m) Annual synergies One-time costs 110 Total 100 90 ~ €85 m p.a. (USD100 m) 80 Annual synergies APD: ~ €68 m p.a. (USD80 m) 70 Huber: ~

  36. Slide 36: Acquisition of Air Products Performance Materials activities

    Slide 36: Acquisition of Air Products Performance Materials activities

    Acquisition of Air Products (APD) Performance Materials activities Creating a global leader in Specialty & Coating Additives Impacted Evonik businesses APD Performance Materials • PU foam stabilizers • PU foam catalysts • Surfactants for care and • Amine-based specialty surfactants Nutrition Creatin

  37. Slide 37: Acquisition of Huber Silica

    Slide 37: Acquisition of Huber Silica

    Acquisition of Huber Silica Access to new highly attractive silica applications for Evonik Evonik‘s focus areas in Silica Huber’s focus areas in Silica Complementary Tire applications Dental Coatings  Attractive growth rates: Life Science Specialties Industrial 4-6% Specialties Combined sales1: > €

  38. Slide 38: Leading in Innovation

    Slide 38: Leading in Innovation

    Leading in Innovation Ambitious targets, clear strategy and inspiring culture Innovation Innovation Innovation Targets Strategy Culture  Increase of innovation pipeline value  Balanced innovation portfolio management  Guiding principles of innovation  16% contribution of innovation  Fostering d

  39. Slide 39: Innovation: Our goals

    Slide 39: Innovation: Our goals

    Innovation: Our goals R&D rate Evonik Innovation Growth Fields 3 % on Group level; €1 billion additional turnover 4-6 % in growth engines by 2025 Our Goals Products/applications younger than five years 16 percent share of overall sales (medium term) 39

  40. Slide 40: Corporate culture drives performance

    Slide 40: Corporate culture drives performance

    Corporate culture drives performance Business focus Best-in-class team  We take action and initiate change  We build on openness, trust and respect  We reward measured risk taking  We assign responsibility and demand  We promise and deliver – with conviction, accountability clarity and consiste

  41. Slide 41: Appendix

    Slide 41: Appendix

    Appendix 1. Strategy Details 2. Segment overview 3. Financials 4. Upcoming events 41

  42. Slide 42: Evonik Group: 22 Business Lines grouped in 3 segments

    Slide 42: Evonik Group: 22 Business Lines grouped in 3 segments

    Evonik Group 22 Business Lines grouped in 3 segments Resource Performance Nutrition & Care Efficiency Materials Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin €4,507 m €747 m / 16.6% €5,393 m €1,173 m / 21.8% €3,751 m €658 m / 17.5% Animal Nutrition Silica Performan

  43. Slide 43: Nutrition & Care

    Slide 43: Nutrition & Care

    Nutrition & Care Fulfilling human needs in a globalizing world Key characteristics Adj. EBITDA (€ m) and margin (%) End market split  High degree of customer intimacy and market know-how 25.8 25.0 22.1 20.8 29.1 23.3 16.6  Enabling our customers to deliver differentiating solutions in their market

  44. Slide 44: Nutrition & Care Business Line overview (1/2)

    Slide 44: Nutrition & Care Business Line overview (1/2)

    Nutrition & Care Business Line overview (1/2) Animal Nutrition Baby Care Personal Care Household Care  Methionine  Superabsorbents  Actives  Fabric conditioners Key  Lysine, Threonine,  Emulsifiers  Specialty surfactants products Tryptophan  Conditioners  Feed additives and services  Baby

  45. Slide 45: Nutrition & Care Business Line overview (2/2)

    Slide 45: Nutrition & Care Business Line overview (2/2)

    Nutrition & Care Business Line overview (2/2) Health Care Comfort & Insulation Interface & Performance  Pharmaceutical coatings  Foam stabilizers  Release coatings Key  Active pharma ingredients  Catalysts  Super spreading additives products  Pharma grade amino acids  Release agents  Drug d

  46. Slide 46: Portfolio Management – Animal Nutrition

    Slide 46: Portfolio Management – Animal Nutrition

    Portfolio Management – Animal Nutrition Advance leadership position by growth initiatives and efficiency gains Strategic review process conducted in Animal Nutrition Broaden Manage Optimize portfolio production setup cost base …beyond amino acids:  Contract manufacturing for  Process innovations t

  47. Slide 47: Investment in digital skin technology start-up mySkin

    Slide 47: Investment in digital skin technology start-up mySkin

    Business Line Personal Care Strengthen Health & Care Growth Engine Investment in American Digital Skin Technology Start-up mySkin Driving digitalization in the cosmetic industry  Minority investment (single digit €) as part of a Series A financing  mySkin’s technology offers the possibility of get

  48. Slide 48: Health Care Pharma Polymers & Services

    Slide 48: Health Care Pharma Polymers & Services

    Business Line Health Care Pharma Polymers & Services Our expertise is the design of medicine Active Pharmaceutical Excipients Ingredient Pharmaceutical Example 1, Solid Oral Dosage Forms: Proton Pump Inhibitors (PPI) Drug product Phase  PPIs are oral drugs for long-lasting reduction of gastric acid

  49. Slide 49: Resource Efficiency

    Slide 49: Resource Efficiency

    Resource Efficiency Innovative products for resource-efficient solutions Key characteristics Adj. EBITDA (€ m) and margin (%) End market split  Focus on performance-impacting and value-driving components 19.9 21.4 21.3 20.7 20.9 21.8 21.8  Minor share of cost in most end products 1,173 Automotive,

  50. Slide 50: Resource Efficiency Business Line overview (1/3)

    Slide 50: Resource Efficiency Business Line overview (1/3)

    Resource Efficiency Business Line overview (1/3) Silica Oil Additives Crosslinkers  Precipitated silica  Lubricant additives (viscosity modifiers)  Crosslinkers for composites, elastomers Key  Fumed silica and coatings products  Special oxides  Silicone rubber  Automotive lubes  Composites M

  51. Slide 51: Resource Efficiency Business Line overview (2/3)

    Slide 51: Resource Efficiency Business Line overview (2/3)

    Resource Efficiency Business Line overview (2/3) Active Oxygens High Performance Polymers Coating & Adhesive Resins  Hydrogen peroxide  High perf. polyamide (PA12)  Functional resins Key  Polyetheretherketone (PEEK)  Adhesive hot melts products  Membranes and Polyimide fibres  Heat sealants 

  52. Slide 52: Resource Efficiency Business Line overview (3/3)

    Slide 52: Resource Efficiency Business Line overview (3/3)

    Resource Efficiency Business Line overview (3/3) Silanes Coating Additives Catalysts  Chlorosilanes  Additives for eco-friendly and high solid  Activated base metal catalysts Key  Organofunctional silanes industrial coatings  Precious metal catalysts products  Rubber silanes  Catalysts for in

  53. Slide 53: Extending Smart Materials growth engine

    Slide 53: Extending Smart Materials growth engine

    Business Line High Performance Polymers Extending Smart Materials growth engine Expansion of Polyamide 12 capacities with new plant complex in Marl (Germany)  Strong strategic fit … expanding growth engine “Smart Materials”  Attractive market … strong growth and demanding applications  Unique mar

  54. Slide 54: PA12 key market examples – Automotive and e-mobility

    Slide 54: PA12 key market examples – Automotive and e-mobility

    Business Line High Performance Polymers PA12 key market examples – Automotive and e-mobility Thermal management as key PA12 growth driver in future automotive Refrigerant lines connected to … Air conditioning system Cooling lines for / to … HV battery pack Cooling lines connected to … Conventional c

  55. Slide 55: PA12 key market examples – 3D Printing

    Slide 55: PA12 key market examples – 3D Printing

    Business Line High Performance Polymers PA12 key market examples – 3D Printing Evonik clear market leader in material for key 3D printing technologies Powder Bed Fusion (SLS, MJF)  Evonik is market leader in powder-based + Best mechanical - Expensive machines processes with 65% market share propert

  56. Slide 56: Strengthening Green Tire Product Portfolio

    Slide 56: Strengthening Green Tire Product Portfolio

    Business Line Silica Strengthening Green Tire Product Portfolio New products to meet market needs for innovative solutions  Evonik is market leader and the only manufacturer worldwide to offer Silica and Rubber Silanes from a single source  Both are most important components for manufacturing gree

  57. Slide 57: Performance Materials

    Slide 57: Performance Materials

    Performance Materials Integrated production platforms for efficient production of rubber and plastic intermediates Key characteristics Adj. EBITDA (€ m) and margin (%) End market split  Strong integrated production platforms  Leading cost positions 18.8 16.9 10.6 8.5 9.0 11.4 17.5  Favorable raw

  58. Slide 58: Performance Materials Business Line overview (1/2)

    Slide 58: Performance Materials Business Line overview (1/2)

    Performance Materials Business Line overview (1/2) Performance Intermediates Methacrylates Acrylic Products  Butadiene  Plasticizers (INA &  Methylmethacrylate (MMA) &  Acrylic sheets and semi-finished Key  MTBE DINP) application monomers products (Plexiglas®/ Acrylite®) products  Butene-1  M

  59. Slide 59: Performance Materials Business Line overview (2/2)

    Slide 59: Performance Materials Business Line overview (2/2)

    Performance Materials Business Line overview (2/2) Agrochemicals & Polymer Additives Functional Solutions CyPlus Technologies  Triacetonamine  Alkoxides  Sodium cyanide Key  Crosslinkers (e.g. sodium methylate)  Potassium cyanide products  Precursors for crop protection  Polymer additives  A

  60. Slide 60: Portfolio Management – Methacrylates

    Slide 60: Portfolio Management – Methacrylates

    Portfolio Management – Methacrylates Divestment of Methacrylates business Business Facts 1.5 #2  Methacrylates in good shape and well positioned ~€ bn globally in MMA and PMMA sales in 2017  C2 technology “LiMA” opens new opportunities for the business Divestment Access to process for 18 sites C2,

  61. Slide 61: Evonik's new C2 technology LiMA

    Slide 61: Evonik's new C2 technology LiMA

    Portfolio Management – Methacrylates Evonik’s new C2 technology “LiMA” – best-in-class MMA production process “LiMA” – Leading in Methacrylates  Intelligent process … minimizes energy and steam requirements  Efficient new catalyst … accesses shale gas as raw-material source for MMA production  Pr

  62. Slide 62: Performance Materials increases productivity

    Slide 62: Performance Materials increases productivity

    Performance Materials increases productivity while exercising tight cost management Productivity increase 2014 - 2017 Strategic measures raising productivity Productivity1  Flexibilization of cost structure and streamlining of product 2014 = 100% +16% portfolio  Site closure Münchsmünster (CO2 ext

  63. Slide 63: Performance Intermediates (C4 chain)

    Slide 63: Performance Intermediates (C4 chain)

    Performance Intermediates (C4 chain) Fully integrated production platform in Europe Capacity overview Share of total sales by product End markets Rubber Fuel additive Specialties Evonik Butadiene Polyethylene product 320 kt MTBE co-monomer 1-Butene 675 kt Plasticizer Butadiene Butene-1 235 kt alcoho

  64. Slide 64: Appendix

    Slide 64: Appendix

    Appendix 1. Strategy Details 2. Segment overview 3. Financials 4. Upcoming events 64

  65. Slide 65: Segment performance FY 2017

    Slide 65: Segment performance FY 2017

    Segment performance FY 2017 Resource Efficiency and Performance Materials with strong earnings growth Nutrition & Care Resource Efficiency Performance Materials Adj. +20% +77% -26% EBITDA (in € m) 1,006 1,173 658 747 977 371 Margin (in %) 23.3 16.6 21.8 21.8 11.4 17.5 2016 2017 2016 2017 2016 2017 S

  66. Slide 66: Recent cost initiatives

    Slide 66: Recent cost initiatives

    Recent cost initiatives Program to achieve cost excellence in admin and selling initiated Scope Cost initiative Administration Excellence Initiative to achieve cost excellence Measures with savings potential Focus on all admin and selling functions Selling, General & Admin >€200 m implemented Projec

  67. Slide 67: Capex 2018

    Slide 67: Capex 2018

    Capex 2018 ~€1 bn despite additional €150 m for Me6 plant Capex development Top growth projects 2018  Methionine 6 (Me6) 1,078  More than half a billion €, 2016-2019 Guidance Singapore ~€ 1 bn  Extension precipitated silica  ~€100 m; 2016-2018 Charleston, South Carolina  Extension of fumed sili

  68. Slide 68: Capex with significant decrease since 2013

    Slide 68: Capex with significant decrease since 2013

    Investments Capex with significant decrease since 2013 – focus on growth segments Capex spending (in € m)  Capex focus on the two growth segments  Sustainable capex level going forward: ~€900 - 950 m  Sizable investment projects will result in slightly elevated levels during project time (e.g. se

  69. Slide 69: Investments: Selective projects announced for 2018/2019

    Slide 69: Investments: Selective projects announced for 2018/2019

    Investments Selective projects announced for 2018/2019 Investment projects successfully completed … … and projects with start-up planned for 2019 Polyimide membrane exp. Veramaris JV (Green Ocean) Austria United States Rationale: strengthen growth in attractive gas separation market and position as

  70. Slide 70: Financial policy

    Slide 70: Financial policy

    Financial policy Maintaining a solid investment grade rating A3/A- Both rating agencies affirmed its ratings in 2017 based on BBB+ (stable)  Strong business profile underpinned by significant size and Baa1/BBB+ leading global market positions Investment Baa1 (stable) grade  Greater-than-peer diver

  71. Slide 71: Debt structure

    Slide 71: Debt structure

    Debt structure Well balanced maturity profile (in € m as of 31 March 2018)  Well balanced debt maturity profile with no 1,000 single maturity greater than €750 m 800  Long-term capital market financing secured under favorable conditions: average coupon 600 of only 0.74% p.a. on €3.15 bn senior bon

  72. Slide 72: Net debt development

    Slide 72: Net debt development

    Net debt development (in € m) Net financial debt Pension provisions Total leverage1  Net financial debt slightly reduced vs. FY 2017  Increase of net financial debt in 2017 mainly driven Net 2,760 3,553 2,251 2,741 6,840 7,271 by acquisition-related purchase price payments debt (in particular APD

  73. Slide 73: Pensions

    Slide 73: Pensions

    Pensions Pension funding overview as of 31 December 2017  Pensions very long-term, patient debt (>16 years) with no funding Unfunded Pension fund / obligations in Germany (~ pension reinsured support provision on 30% 31% fund  DBO level of €11.6 bn yoy stable balance sheet) (interest rate unchange

  74. Slide 74: Pensions: Sensitivity to discount rate changes

    Slide 74: Pensions: Sensitivity to discount rate changes

    Pensions Sensitivity to discount rate changes Sensitivity analysis1: Increase (decrease) in discount rate by 100 bp in year x Impact in year x Impact in year x+1  Personnel costs: no impact  Personnel costs: decrease (increase) due to lower (higher) service costs  Finance costs: no impact  Finan

  75. Slide 75: Pensions: Breakdown of P&L and cash flow effects

    Slide 75: Pensions: Breakdown of P&L and cash flow effects

    Pensions Breakdown of P&L and cash flow effects in € m P&L item / KPI 2016 2017 Annual report ‘17 Current service costs Adj. EBITDA -180 -200 p. 131 Interest costs Net interest expense -297 -243 p. 131 P&L Exp. return on plan assets Net interest expense +207 +166 p. 132 Other Adj. EBITDA -44 -33 p.

  76. Slide 76: Transition of changes in provisions for pensions

    Slide 76: Transition of changes in provisions for pensions

    Transition of “Changes in provisions for pensions” in Operating Cash Flow Pension expenses included in Delta as part EBIT (starting point for CF) Cash-outs for Defined Benefit plans of OCF – no cash out 33 200 233 -252 -202 -462 -438 +210 -186 Service Costs Others Non-cash Benefits paid Benefits pai

  77. Slide 77: Financial track record

    Slide 77: Financial track record

    Financial track record Sales (in € m) Adj. EBITDA (in € m) / margin1 Carbon Black/Real Estate 16.1% 18.3% 19.0% 18.5% 15.7% 14.6% 18.2% 17.0% 16.4% 13,300 14,540 13,365 12,708 12,917 13,507 12,732 14,383 2,365 2,768 2,467 2,465 2,165 2,357 10,518 1,989 1,882 1,607 11,701 13,316 2,439 9,267 2,022 1,3

  78. Slide 78: Segment overview by quarter

    Slide 78: Segment overview by quarter

    Segment overview by quarter Sales (in € m) Q4/16 FY 2016 Q1/17 Q2/17 Q3/17 Q4/17 FY 2017 Q1/18 Nutrition & Care 1,093 4,316 1,120 1,163 1,110 1,114 4,507 1,119 Resource Efficiency 1,081 4,473 1,360 1,367 1,358 1,308 5,393 1,398 Performance Materials 846 3,245 959 910 913 970 3,751 995 Services 180 6

  79. Slide 79: Raw material split

    Slide 79: Raw material split

    Raw material split Total procurement volume 2017 (in € m) Breakdown of raw material spend1 (examples) Bio Logistic & Packaging  Dextrose Energy (incl. natural gas)  Fatty alcohols  Tallow fatty acid Fossil  Fatty acids  Crack C4  tallow  Propylene ~€5.4 bn  Acrylic acid ~€9.1 bn Machincery 

  80. Slide 80: Management compensation

    Slide 80: Management compensation

    Management compensation Fixed salary  To be paid in cash for each financial year on a monthly basis ~1/3  Pay-out calculated on the basis of the achievement of  Factor of between 0.8 and 1.2 to take into account the focused KPIs; aligned to mid-term strategic targets: achievement of further indiv

  81. Slide 81: Six strong Innovation Growth Fields

    Slide 81: Six strong Innovation Growth Fields

    Six strong Innovation Growth Fields within the growth engines Leveraging our core competencies into new highly attractive markets Growth engines Innovation Growth Fields more Additional contribution to than sales from all six Innovation €1 billion Growth Fields by 2025 81

  82. Slide 82: Our sustainability targets 2017 and beyond

    Slide 82: Our sustainability targets 2017 and beyond

    Our sustainability targets 2017 and beyond Strategy and Growth Governance and Compliance Employees  Development of methods and  20% women at 1st and 2nd  Establish a learning strategy for indicators for sustainable management level below Executive the ongoing development of portfolio management B

  83. Slide 83: Ratings & Rankings: Evonik well positioned

    Slide 83: Ratings & Rankings: Evonik well positioned

    Ratings & Rankings: Evonik well positioned Our commitment has been recognized by  CDP Climate Change (A-, Index-Leader MDAX)  CDP Water (B)  Oekom Research (prime standard B-)  Sustainalytics (among Top 5 within chemical sector)  Together for Sustainability/ecoVadis (“Gold Standard”)  FTSE4Goo

  84. Slide 84: Appendix

    Slide 84: Appendix

    Appendix 1. Strategy 2. Segment overview 3. Financials 4. Upcoming events 84

  85. Slide 85: Capital Markets Day

    Slide 85: Capital Markets Day

    Save the date Capital Markets Day Essen 13/14 September 2018 85

  86. Slide 86: Upcoming IR events

    Slide 86: Upcoming IR events

    Upcoming IR events Conferences & Roadshows Upcoming Events & Reporting Dates 16 May Roadshow, London 23 May AGM 16-17 May Roadshow, Milan/Lugano 2 August Q2 2018 reporting 28 May Roadshow, Paris 13/14 September Capital Markets Day 5 June mBank Conference, Warsaw 6-7 June Deutsche Bank Conference, Be

  87. Slide 87: Evonik Investor Relations team

    Slide 87: Evonik Investor Relations team

    Evonik Investor Relations team Tim Lange Janine Kanotowsky Head of Investor Relations Team Assistant +49 201 177 3150 +49 201 177 3146 tim.lange@evonik.com janine.kanotowsky@evonik.com Eva Frerker Daniel Györy Kai Kirchhoff Investor Relations Manager Investor Relations Manager Investor Relations Man

  88. Slide 88: Disclaimer

    Slide 88: Disclaimer

    Disclaimer In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the oper

  89. Slide 89: © evonik

    Slide 89: © evonik

    © evonik

Source: Internet Archive copy of corporate.evonik.de

More decks from Evonik Industries AG

All 19 Evonik Industries decks